OTCMKTS:USRMUS Stem Cell Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding US Stem Cell Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.0053 0.00 (0.00 %) (As of 07/14/2020 01:27 PM ET) Add Compare Share Today's Range$0.01Now: $0.01▼$0.0150-Day Range$0.01MA: $0.01▼$0.0152-Week Range$0.00Now: $0.01▼$0.02Volume726,100 shsAverage Volume408,784 shsMarket Capitalization$2.28 millionP/E RatioN/ADividend YieldN/ABeta3.49 ProfileAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States and internationally. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for US Stem Cell. Previous Next 2.8 Community Rank Outperform VotesUS Stem Cell has received 132 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUS Stem Cell has received 105 “underperform” votes. (Add your “underperform” vote.)Community SentimentUS Stem Cell has received 55.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about US Stem Cell and other stocks. Vote “Outperform” if you believe USRM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe USRM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUS Stem Cell does not currently pay a dividend.Dividend GrowthUS Stem Cell does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, US Stem Cell insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 16.72% of the stock of US Stem Cell is held by insiders. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.56 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:USRM Previous SymbolNASDAQ:BHRT CUSIPN/A CIKN/A Webwww.us-stemcell.com Phone954-835-1500Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.70 million Price / Sales0.34 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-0.27Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees10 Outstanding Shares429,700,000Market Cap$2.28 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable OTC:USRM Rates by TradingView Receive USRM News and Ratings via Email Sign-up to receive the latest news and ratings for USRM and its competitors with MarketBeat's FREE daily newsletter. US Stem Cell (OTCMKTS:USRM) Frequently Asked Questions How has US Stem Cell's stock been impacted by COVID-19 (Coronavirus)? US Stem Cell's stock was trading at $0.0061 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, USRM shares have decreased by 13.1% and is now trading at $0.0053. View which stocks have been most impacted by Coronavirus. When is US Stem Cell's next earnings date? US Stem Cell is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for US Stem Cell. How were US Stem Cell's earnings last quarter? US Stem Cell Inc (OTCMKTS:USRM) posted its quarterly earnings data on Wednesday, August, 7th. The company reported $0.00 earnings per share for the quarter. The firm had revenue of $1.30 million for the quarter. View US Stem Cell's earnings history. Has US Stem Cell been receiving favorable news coverage? News articles about USRM stock have trended somewhat positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. US Stem Cell earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about US Stem Cell. Who are some of US Stem Cell's key competitors? Some companies that are related to US Stem Cell include Geovax Labs (GOVX), Vitality Biopharma (VBIO), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC). View all competitors. What other stocks do shareholders of US Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other US Stem Cell investors own include Actinium Pharmaceuticals (ATNM), Cleveland BioLabs (CBLI), Digi International (DGII), Micron Technology (MU), SeaChange International (SEAC), SMTC (SMTX), Alexion Pharmaceuticals (ALXN), Aphria (APHA), AquaBounty Technologies (AQB) and Axsome Therapeutics (AXSM). Who are US Stem Cell's key executives? US Stem Cell's management team includes the following people: Mr. Michael Tomas, CEO, Pres, CFO & Director (Age 53)Dr. Kristin C. Comella Ph.D., Chief Science Officer & Director (Age 42)Dr. Colleen Robb, Sr. Compliance OfficerMr. Phil Posa, Sr. VP of U.S. & International SalesMs. Evelyn Flores, Corp. Controller What is US Stem Cell's stock symbol? US Stem Cell trades on the OTCMKTS under the ticker symbol "USRM." How do I buy shares of US Stem Cell? Shares of USRM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is US Stem Cell's stock price today? One share of USRM stock can currently be purchased for approximately $0.01. How big of a company is US Stem Cell? US Stem Cell has a market capitalization of $2.28 million and generates $6.70 million in revenue each year. US Stem Cell employs 10 workers across the globe. What is US Stem Cell's official website? The official website for US Stem Cell is www.us-stemcell.com. How can I contact US Stem Cell? US Stem Cell's mailing address is 1560 SAWGRASS CORPORATE PKWY 4TH FLOOR, SUNRISE FL, 33325. The company can be reached via phone at 954-835-1500 or via email at [email protected] This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
